Eloxx Pharmaceuticals (ELOX) CEO boosts share ownership via option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Eloxx Pharmaceuticals’ President and CEO Sumit Aggarwal reported a series of compensation-related equity moves. On February 28, 2026, he exercised options to acquire 260,946 shares of common stock at $0.15 per share, bringing his directly held common stock to 1,672,756 shares.
Earlier, on January 24, 2026, 15,000 restricted stock units converted into an equal number of common shares. On September 19, 2025, he received an award of 1,000,000 common shares and 3,597,090 stock options with a $0.15 exercise price expiring in 2035. On August 14, 2025, he exercised options to acquire 196,880 shares at an exercise price of $0.0001 per share.
Footnotes state that several older options granted in 2021–2023 were cancelled and replaced with new options at lower exercise prices, and that the board accelerated vesting or waived performance conditions in connection with certain exercises and grants.
Positive
- None.
Negative
- None.
Insider Trade Summary
472,826 shares exercised/converted
Mixed
20 txns
Insider
Aggarwal Sumit
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 260,946 | $0.00 | -- |
| Exercise | Common Stock | 260,946 | $0.15 | $39K |
| Exercise | Restricted Stock Units | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 3,597,090 | $0.00 | -- |
| Grant/Award | Common Stock | 1,000,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 60,390 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 68,700 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 42,790 | $0.00 | -- |
| Exercise | Common Stock | 196,880 | $0.0001 | $19.69 |
| Disposition | Stock Option (Right to Buy) | 42,790 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 42,790 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 35,580 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 35,580 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 24,810 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 24,810 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 68,700 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 68,700 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 42,790 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,336,144 shares (Direct, null);
Common Stock — 1,672,756 shares (Direct, null);
Restricted Stock Units — 15,000 shares (Direct, null)
Footnotes (1)
- Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price. The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price. The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price. The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise. The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.
Key Figures
Latest option exercise: 260,946 shares at $0.15
Direct common shares after latest exercise: 1,672,756 shares
RSUs converted: 15,000 shares
+5 more
8 metrics
Latest option exercise
260,946 shares at $0.15
Common stock acquired on February 28, 2026
Direct common shares after latest exercise
1,672,756 shares
Common stock beneficially owned after February 28, 2026
RSUs converted
15,000 shares
RSUs converting into common stock on January 24, 2026
Large common stock grant
1,000,000 shares
Awarded on September 19, 2025
Large option grant
3,597,090 options at $0.15
Stock options expiring September 19, 2035
Prior option exercise
196,880 shares at $0.0001
Common stock acquired on August 14, 2025
Total derivative exercises
472,826 shares
Exercise shares across M-code transactions in summary
Transaction directions
16 acquisitions, 4 dispositions
Counts from transaction summary
Key Terms
restricted stock units, reverse stock split, stock option (Right to Buy), exercise price, +2 more
6 terms
restricted stock units financial
"Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
reverse stock split financial
"On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split."
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
stock option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security shares of common stock."
exercise price financial
"in exchange for a new option having a lower exercise price."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested and became exercisable financial
"The stock option vested and became exercisable over the four-year period"
accelerated vesting financial
"The Board accelerated vesting on the unvested portion in connection with the exercise."
FAQ
What did Eloxx (ELOX) CEO Sumit Aggarwal report on February 28, 2026?
He exercised stock options to acquire 260,946 shares of Eloxx common stock at an exercise price of $0.15 per share. After this transaction, his directly held common stock position increased to 1,672,756 shares, according to the Form 4 data.
What major equity awards did the Eloxx (ELOX) CEO receive on September 19, 2025?
On September 19, 2025, he received a grant of 1,000,000 shares of common stock and 3,597,090 stock options with a $0.15 exercise price expiring on September 19, 2035. These awards significantly increased his potential equity exposure to Eloxx.
What are the key details of the August 14, 2025 Eloxx (ELOX) option exercise?
On August 14, 2025, Aggarwal exercised options to acquire 196,880 shares of Eloxx common stock at an exercise price of $0.0001 per share. After this transaction, his directly held common stock position was reported as 396,810 shares.
How were older Eloxx (ELOX) stock options adjusted for the CEO?
Footnotes explain that Aggarwal agreed to cancel certain options granted in 2021–2023 in exchange for new options with lower exercise prices. The board also accelerated vesting or waived performance criteria in connection with some exercises and regranting activities.
What does the Eloxx (ELOX) Form 4 show about RSUs held by the CEO?
The filing notes a grant of 15,000 restricted stock units that was fully vested on grant. Each RSU represented a right to receive one common share, and on January 24, 2026, those 15,000 RSUs converted into 15,000 shares of Eloxx common stock.